CTLA4 and melanoma: It is critically important to reduce death rates in melanoma patients who develop resistance to targeted therapy, and salvage therapies such as immunotherapy with inhibitors of cytotoxic T cell antigen 4 (CTLA-4) and programmed death 1 (PD-1) checkpoints are used in clinics [12].